Chemotherapy for metastatic breast cancer-report of a European expert panel.

[1]  C. Seynaeve,et al.  Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane , 2001, Breast Cancer Research and Treatment.

[2]  I. Tannock,et al.  Third line chemotherapy in patients with metastatic breast cancer: an evaluation of quality of life and cost , 1999, Breast Cancer Research and Treatment.

[3]  David Miles,et al.  Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Blackstein,et al.  Gemcitabine as First-Line Therapy in Patients with Metastatic Breast Cancer: A Phase II Trial , 2002, Oncology.

[5]  G. Peters,et al.  Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. , 2002, European journal of cancer.

[6]  L. Zelek,et al.  Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma , 2001, Cancer.

[7]  A. Buzdar,et al.  Multicenter, Phase II study of capecitabine in taxane‐pretreated metastatic breast carcinoma patients , 2001, Cancer.

[8]  L. Zelek,et al.  Single-agent estramustine phosphate (EMP) is active in advanced breast cancer after failure with anthracyclines and taxanes. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  A. Buzdar,et al.  Capecitabine (Xeloda) in 162 patients with paclitaxel-pretreated mbc: updated results and analysis of dose modification , 2001 .

[10]  S. Frings,et al.  Capecitabine: The new standard in metastatic breast cancer failing anthracycline and taxane-containing chemotherapy? Mature results of a large multicenter phase II trial , 2001 .

[11]  V. Lorusso,et al.  Phase II study of vinorelbine with protracted fluorouracil infusion as a second- or third-line approach for advanced breast cancer patients previously treated with anthracyclines. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  L. Balducci.  Geriatric oncology: challenges for the new century. , 2000, European journal of cancer.

[13]  D. Crivellari,et al.  Combination chemotherapy with navelbine and continuous infusion of 5-fluorouracil in metastatic, chemotherapy refractory breast cancer. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  G. Pacilio,et al.  A Phase II Study of Paclitaxel/Cisplatin Combination in Patients with Metastatic Breast Cancer Refractory to Anthracycline-Based Chemotherapy , 2000, Tumori.

[15]  V. Gebbia,et al.  Gemcitabine and vinorelbine in pretreated advanced breast cancer: a pilot study. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  J. Klijn,et al.  Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Bonneterre,et al.  Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  L. Zelek,et al.  Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  K. Friedrichs,et al.  Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  A. Irvine,et al.  Infusional 5-fluorouracil can be a pain in the neck: A case for repositioning displaced Hickman lines. , 1999, Clinical oncology (Royal College of Radiologists (Great Britain)).

[21]  J. Bergh,et al.  Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. , 1999, European journal of cancer.

[22]  O. Sezer,et al.  Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. , 1999, Anti-cancer drugs.

[23]  P. Prandoni,et al.  Upper extremity deep vein thrombosis. , 1999, Current opinion in pulmonary medicine.

[24]  D. Richel,et al.  Prospective Randomized Trial of Docetaxel Versus Mitomycin Plus Vinblastine in Patients With Metastatic Breast Cancer Progressing Despite Previous Anthracycline-Containing Chemotherapy , 1999 .

[25]  B. Dörken,et al.  Brain metastases in breast cancer: prognostic factors and management. , 1999, European journal of cancer.

[26]  E. Salminen,et al.  Docetaxel: standard recommended dose of 100 mg/m(2) is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy-A phase II single-center study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  A. Buzdar,et al.  Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  V Torri,et al.  Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  G. Hortobagyi,et al.  Treatment of breast cancer. , 1998, The New England journal of medicine.

[30]  G. Hortobagyi,et al.  A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[32]  D. Tu,et al.  Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  M. Ratain,et al.  Oral chemotherapy: rationale and future directions. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  R. Coombes,et al.  Docetaxel: response in patients who have received at least two prior chemotherapy regimens for metastatic breast cancer. , 1998, European journal of cancer.

[35]  R. Carlson.  Quality of life issues in the treatment of metastatic breast cancer. , 1998, Oncology.

[36]  J. Blay,et al.  Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline‐ and/or paclitaxel‐containing regimens , 1998, Cancer.

[37]  C. Topham,et al.  Patient preferences for chemotherapy schedules used in the treatment of advanced colorectal cancer--a pilot study. , 1997, European journal of cancer care.

[38]  M. Sabel,et al.  Principles of chronic venous access: recommendations based on the Roswell Park experience. , 1997, Surgical oncology.

[39]  M. Colleoni,et al.  Mitomycin C and Vinorelbine in Pretreated Breast Cancer , 1997, Tumori.

[40]  R. Livingston,et al.  Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  A. Norman,et al.  A prospective analysis of 949 long-term central venous access catheters for ambulatory chemotherapy in patients with gastrointestinal malignancy. , 1997, European journal of cancer.

[42]  E. Warner,et al.  Patient preferences for oral versus intravenous palliative chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  W. Bemelman,et al.  Complications of an implantable venous access device (Port-a-Cath) during intermittent continuous infusion of chemotherapy. , 1996, European journal of cancer.

[44]  G. Hortobagyi,et al.  Current management of advanced breast cancer. , 1996, Seminars in oncology.

[45]  R. Lowenthal,et al.  Home chemotherapy for cancer patients: cost analysis and safety , 1996, The Medical journal of Australia.

[46]  L. Norton,et al.  Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  P. Fumoleau,et al.  Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  A. Vincent-Salomon,et al.  Meningeal carcinomatosis in patients with breast carcinoma: Clinical features, prognostic factors, and results of a high‐dose intrathecal methotrexate regimen , 1996, Cancer.

[49]  C. Dittrich,et al.  Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel – a phase II study , 1996, Cancer Chemotherapy and Pharmacology.

[50]  A. Harris,et al.  Advanced breast cancer: a phase II trial with gemcitabine. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  P. Schweitzer,et al.  Radiation therapy-induced cardiac injury. , 1995, American heart journal.

[52]  P. Lønning,et al.  Treatment of relapse of breast cancer after adjuvant systemic therapy--review and guidelines for future research. , 1994, European journal of cancer.

[53]  S. Ebbs,et al.  Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. , 1993, British Journal of Cancer.

[54]  S. Payne.  A study of quality of life in cancer patients receiving palliative chemotherapy. , 1992, Social science & medicine.

[55]  M. F. Chen,et al.  Heart diseases following radiotherapy. , 1991, Journal of the Formosan Medical Association = Taiwan yi zhi.

[56]  I. Henderson,et al.  Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  A. Howell,et al.  The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. , 1988, European journal of cancer & clinical oncology.

[58]  J. Doroshow,et al.  A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  Yoshiaki Tsukada,et al.  Central nervous system metastasis from breast carcinoma autopsy study , 1983, Cancer.